Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
5th ed, by Chris H. Polman, W. Ian McDonald, Alan J. Thompson, and T. Jock Murray, 148 pp, $24.95, Demos Medical Publishing Inc, New York, NY, 2001.
Writing a book in a quickly changing field becomes a difficult task for an author. Within the last decade, the basic concepts of many neurological diseases have changed rapidly. These changes have evolved through new knowledge of the genetic code, greater understanding of immunological processes, and novel research techniques. The integration of these factors has rapidly advanced our knowledge of certain subjects and the science of neuroimmunology has been at the forefront of these discoveries. Basic research into the complexities involved, examination of immune defects in other autoimmune diseases, and examination of the results of successful and unsuccessful treatment trials have led to a greater depth of understanding of the immune system. Despite all of these advances, the complete neuroimmunological picture evades us. This is certainly true for multiple sclerosis (MS). Recent research into the pathogenesis in MS has changed many of our perceptions of the disease and changes in treatment paradigms have followed. Despite this exponential progress and the advent of numerous well-designed, controlled studies on the subject, many uncertainties and controversies still exist.
Hawker K. Multiple Sclerosis: A Guide to Treatment and Management. Arch Neurol. 2002;59(6):1039–1040. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: